Loading
Aglatimagene besadenovec is an experimental gene therapy from Candel Therapeutics in phase 3 trials for non-small-cell lung cancer and prostate cancer, with its target not yet stated publicly.
Aglatimagene besadenovec (CAN-2409) is a gene therapy developed by Candel Therapeutics. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. The sponsor states: An adenovirus-based immunotherapy (AdV-tk/CAN-2409) that blocks DNA synthesis in dividing tumour cells, causing tumour cell death, while adenovirus capsid proteins attract immune cells to the tumour microenvironment so activated immune cells can then attack distant metastases. ClinicalTrials.gov describes the intervention as: Aglatimagene besadenovec will be delivered to the prostate via trans-rectal ultrasound guided injection followed by 14 days of oral prodrug, valacyclovir. The second aglatimagene besadenovec injection will be 2-3 weeks after the first follo. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07660094 (Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)), in non-small-cell lung cancer and prostate cancer. The largest, NCT07660094, plans to enrol 500 participants with primary completion expected 2031-10-22. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
An adenovirus-based immunotherapy (AdV-tk/CAN-2409) that blocks DNA synthesis in dividing tumour cells, causing tumour cell death, while adenovirus capsid proteins attract immune cells to the tumour microenvironment so activated immune cells can then attack distant metastases.
1.Aglatimagene besadenovec slips into a pocket on its target.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Aglatimagene besadenovec" OR ABSTRACT:"Aglatimagene besadenovec" OR TITLE:"CAN-2409" OR ABSTRACT:"CAN-2409" OR TITLE:"AdV-tk" OR ABSTRACT:"AdV-tk") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Aglatimagene besadenovec, not a curated reading list.
Shares Oncolytic viruses, Non-small-cell lung cancer and the tag pipeline.
Shares Prostate cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Prostate cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Prostate cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Prostate cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Oncolytic viruses and the tag pipeline.
Shares Oncolytic viruses and the tag pipeline.
Shares Oncolytic viruses and the tag pipeline.